Scinovex
article Open AccessTop 1% cited

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

Science Translational Medicine · 2017 · Vol. 9(399)
Donald M. O’RourkeMacLean P. NasrallahArati DesaiJ. Joseph MelenhorstKeith G. MansfieldJennifer J.D. MorrissetteMaría Martínez-LageSteven BremEileen MaloneyAngela ShenRandi IsaacsSuyash MohanGabriela PlesaSimon F. LaceyJean‐Marc NavenotZhaohui ZhengBruce L. LevineHideho OkadaCarl H. JuneJennifer L. BrogdonMarcela V. Maus

Abstract

A trial of autologous T cells redirected to a specific mutation in glioblastoma patients illustrates mechanisms of resistance.

CAR-T cell therapy researchNanowire Synthesis and ApplicationsVirus-based gene therapy researchGlioblastomaAntigenCancer researchMedicineMutationImmunologyBiologyGeneGenetics
Citations
1,724
FWCI
58.52
field-weighted impact
References
51
Percentile
100%
vs. same field & year
Citations per year
Cited by
Management of glioblastoma: State of the art and future directions
CA A Cancer Journal for Clinicians · 2020 · 1,989 citations
Delivery technologies for cancer immunotherapy
Nature Reviews Drug Discovery · 2019 · 2,556 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma · Scinovex